Attendee search 

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.

CEDEM AG is a privately-owned international pharmaceutical company. We manufacture and supply healthcare and pharmaceutical products. We work on promoting improved health and wellness through our wide range of groundbreaking food supplements to medical devices and personal care products. Our products range from health supplements such as vitamins, minerals and herbal medicines to medical kits, medical equipment, personal care products and cosmetics. We supply our brand to retailers and wholesale distributors in Europe specially emerging markets.